Atlas Analytics · EMA GCP inspections

EMA Annual Report: GCP inspections by region and site type

EMA coordinated 67 Good Clinical Practice inspections in 2023, according to the GCP Inspectors Working Group annual report data in Atlas. 58 were routine and 9 were non-routine. 23 took place in the EU/EEA and 19 in Asia, and 46 of the 67 were at clinical investigator sites.

Unlock the full dashboard

EMA GCP Inspectors Working Group annual report data, compiled by Atlas · 2021 to 2023 · figures read October 14, 2026

AAtlas Analytics/ EMA Annual ReportData as of Oct 14, 2026

EMA Annual Report

Year

2023

Finding grade

All

Category

All

67

GCP inspections, 2023

58

Routine inspections

9

Non-routine inspections

69%

At clinical investigator sites

GCP inspections by region, 2023

  • EU/EEAall routine23
  • Asia12 routine, 7 non-routine19
  • North Americaall routine12
  • Western Europe, non-EU5
  • Africa2 routine, 2 non-routine4

Eastern Europe, Oceania and Latin America

Unlock

GCP inspections by type of site, 2023

  • Clinical investigator46
  • Sponsor17
  • Analytical lab, BE/BA3
  • CRO1

Findings by main category and grade

In the complete dashboard

Critical, major and minor findings for computer systems, IMPs, ethics committees and more, 2021 to 2023.

Unlock

Findings by sub-category

In the complete dashboard

Monitoring, contracts, direct access to data, clinical study reports and more.

Unlock

Three-year trend

In the complete dashboard

Inspection counts and finding grades for 2021, 2022 and 2023.

Unlock
InspectionsFindingsSub-categoriesTrendsPage 1 of 4

Complete dashboard

Get the full dashboard for your team

This page shows a free window. Share your work email and our team will send access to the complete dashboard, including:

  • Critical, major and minor findings by category
  • Findings by sub-category, such as monitoring and data access
  • 2021 and 2022 inspections
  • Three-year trends by grade
  • Filters by category and grade
Book a demo

Where EMA inspected clinical trials in 2023

The EU/EEA and Asia account for 42 of the 67 GCP inspections EMA coordinated in 2023. Every EU/EEA and North American inspection was routine, while 7 of the 19 in Asia were non-routine, meaning they were triggered by a specific concern rather than scheduled.

For sponsors running global trials, that split matters: Asian investigator sites are the most likely to face a triggered inspection. Our list of what inspectors look for applies to GCP as much as GMP.

EMA GCP inspections by region, 2023.
RegionTotalRoutineNon-routine
EU/EEA23230
Asia19127
North America12120
Western Europe, non-EU550
Africa422
Eastern Europe, non-EU220
Oceania220

Which sites EMA inspects

Clinical investigator sites took 46 of the 67 inspections, more than two in three. Sponsors followed with 17. Bioequivalence and analytical labs and contract research organisations made up the rest. A mock inspection scoped around the investigator site is the most useful rehearsal for a trial team.

EMA GCP inspections by type of site, 2023.
Type of siteInspections
Clinical investigator46
Sponsor17
Analytical lab, BE/BA3
CRO1

Frequently asked questions

How many GCP inspections does EMA coordinate each year?

EMA coordinated 67 Good Clinical Practice inspections in 2023 according to the GCP Inspectors Working Group annual report data, 58 routine and 9 non-routine. Most took place in the EU/EEA and Asia.

What is the difference between a routine and a non-routine GCP inspection?

A routine inspection is scheduled as part of a marketing authorisation review. A non-routine, or triggered, inspection follows a specific concern, such as suspected data problems or a serious breach. In 2023, 7 of EMA's 9 non-routine GCP inspections were in Asia.

Which sites does EMA inspect most for GCP?

Clinical investigator sites, with 46 of 67 inspections in 2023. Sponsors were next with 17, followed by bioequivalence and analytical labs and contract research organisations.

How do EMA GCP inspections compare with FDA inspections?

Both check that trial data are reliable and subjects are protected, but the FDA classifies outcomes as NAI, VAI or OAI while EMA grades individual findings as critical, major or minor. See FDA inspection classifications explained for the FDA side.

How do I get the full EMA findings data?

Enter your work email in the dashboard above. The full view adds findings by category, sub-category and grade, 2021 and 2022, and three-year trends. Our team reviews each request and replies by email.